Related references
Note: Only part of the references are listed.Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)
A. J. Scheen et al.
DIABETIC MEDICINE (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
2-Year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with Type 2 diabetes
Jochen Seufert et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
PROactive: time for a critical appraisal
D. John Betteridge et al.
EUROPEAN HEART JOURNAL (2008)
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
Linda G. Mellbin et al.
EUROPEAN HEART JOURNAL (2008)
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
Erland Erdmann et al.
DIABETES CARE (2007)
Rosiglitazone RECORD study: glucose control outcomes at 18 months
P. D. Home et al.
DIABETIC MEDICINE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pioglitazone - A review of its use in type 2 diabetes mellitus
J Waugh et al.
DRUGS (2006)
Resistance to insulin therapy among patients and providers - Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study
M Peyrot et al.
DIABETES CARE (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
B Charbonnel et al.
DIABETOLOGIA (2005)
Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes
MH Tan et al.
DIABETES CARE (2005)
Clinical inertia in response to inadequate glycemic control - Do specialists differ from primary care physicians?
BR Shah et al.
DIABETES CARE (2005)
Oral antidiabetic agents - Current role in type 2 diabetes mellitus
AJ Krentz et al.
DRUGS (2005)